Financing ·
PRF Technologies raised $10 million through an equity line facility on May 28, 2026, to strengthen its balance sheet
PRFXPRF Technologies Ltd.
PRF Technologies raised $10 million through an equity line facility on May 28, 2026, to strengthen its balance sheet. The company's biotechnology subsidiary, LayerBio, is preparing for a Phase 2 clinical trial of OcuRing™-K, while its renewable energy platform, DeepSolar, has validated its Predict™ platform with European market data. PRF Technologies operates in the biotechnology and renewable energy sectors through its dual business model of drug-delivery systems and AI-driven energy optimization technologies.